
Project Mosaic: a new paradigm of personalized ALS medicine
Donation protected
All proceeds will go to project mosaic, which is a research project organized by Mosaic Neuroscience Inc, a public benefit corporation.
ALS is a devastating disease that robs those affected of their ability to move, speak, eat, and breathe. It’s a brutal, progressive disease with no cure and no effective treatments for 99% of patients – 99% of clinical trials fail. Most people die within 2–5 years.
Since being diagnosed in 2020, my friend, Bernie Zipprich, has been working feverishly to change this outlook. Last year, Bernie launched Project Mosaic, a research initiative to solve one of the biggest problems in ALS drug development: the models we use to develop treatments don’t reflect the real complexity of the disease.
Like cancer, ALS is a mosaic of overlapping conditions. But ALS drug development often ignores this, leading to high rates of failure (10x higher than trials of drugs for other CNS conditions).
Using stem cell technology, we can now recreate a patient’s unique version of ALS in a dish — kind of like a biopsy for the brain. That opens the door to precision treatments, faster drug discovery, and better clinical trials — not just for ALS, but also for Alzheimer’s, Parkinson’s, and beyond. Multiple academic labs have published proofs of concept.
We have the team, the plan, the advisors, and the partners. Now, we just need the funding to replicate those findings and prove it can work at an industrial scale.
In this difficult funding environment, we need your help to get started. We are urgently trying to raise $185,000 to jumpstart the work and generate the preliminary data we need to unlock broader support.
Your donations will allow us to jumpstart our work. We’ll be able to:
- Purchase the stem cell lines we need
- Get at least one lab up and running
- Generate the preliminary data we need — we hope by year end
If we succeed, the future of ALS treatment will look radically different:
- Patients will receive personalized drug regimens based on the information encoded in their cells.
- Drug makers will be able to run faster, smarter trials.
- More treatments will succeed — and faster.
And this precision medicine approach could extend to Alzheimer’s, Parkinson’s, and beyond.
But first, we need to generate preliminary data to convince the field that what’s been demonstrated in academic labs can be scaled to industry.
And for that, we need your help. In these difficult times, please help progress continue. Please help us bring badly needed precision drugs to the fight against ALS and other devastating neurodegenerative disorders.
Please donate if you can — and share if you’re moved. Every dollar helps. Every share helps. We are fighting for millions of lives. Thank you for your support from the bottom of my heart.
Co-organizers (3)
Anjali Lalwani
Organizer
New York, NY
Bernie Zipprich
Beneficiary
Bernie Zipprich
Co-organizer